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Background: The Mothers After Gestational Diabetes in Australia Diabetes Prevention Program (MAGDA-DPP) is a
randomized controlled trial (RCT) that aims to assess the effectiveness of a structured diabetes prevention
intervention for women who had gestational diabetes.
Methods/Design: The original protocol was published in Trials (http://www.trialsjournal.com/content/14/1/339).
This update reports on an additional exclusion criterion and change in first eligibility screening to provide greater
clarity. The new exclusion criterion “surgical or medical intervention to treat obesity” has been added to the original
protocol. The risks of developing diabetes will be affected by any medical or surgical intervention as its impact on
obesity will alter the outcomes being assessed by MAGDA-DPP. The screening procedures have also been updated
to reflect the current recruitment operation. The first eligibility screening is now taking place either during or after
pregnancy, depending on recruitment strategy.
Trial registration: Australian New Zealand Clinical Trials Registry ANZCTRN 12610000338066.
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Introduction
The Mothers After Gestational Diabetes in Australia
Diabetes Prevention Program (MAGDA-DPP) is a ran-
domized controlled trial (RCT) aiming to assess the effect-
iveness of a structured diabetes prevention intervention
for women with previous gestational diabetes (GDM). The
MAGDA-DPP trial offers an evidence-based structured
lifestyle modification group intervention for such women.
The objectives of MAGDA-DPP are that the intervention
will result in favourable changes, relative to usual care, in
clinical-, behavioural-, and patient-relevant outcomes. In* Correspondence: director@greaterhealth.org
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acteristics predictive of successful outcomes.
The MAGDA-DPP intervention is coordinated from
Deakin University (Melbourne Campus). The project in-
cludes multiple study partners, consisting of two State
Governments, three universities, and two non-government
organizations. Ethical approvals have been obtained from
multiple ethics authorities of the MAGDA project partners
for the original study, with the lead ethics review authority
being Deakin University Human Research Ethics Commit-
tee (reference number 2010–005).
The original protocol for the study has been presented
by Shih et al. [1]. Following the publication of the proto-
col, amendments have been made to reflect the changes
to initial screening and recruitment processes and pro-
vide greater protocol clarity. The two changes are out-
lined below. The amendments of the protocol have alsod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Ethics Committee in 2014. Informed consents have been
obtained from all study participants.
Selection of participants
A new exclusion criterion has been added into the proto-
col “surgical or medical intervention to treat obesity”. Any
medical or surgical intervention that impacts on the level
of obesity, such as gastric banding, will alter the risks of
developing diabetes and thus impact the outcomes being
assessed by the MAGDA-DPP trial. Consequently, poten-
tial participants undergoing such an intervention will
need to be excluded. The exclusion criteria are now:
(i) pre-existing diabetes (Type 1 diabetes mellitus or
T2DM); (ii) cancer (not in remission); (iii) severe mental
illness; (iv) substance abuse (illicit drugs); (v) myocardial
infarction in the last three months; (vi) difficulty with
English; (vii) involvement in a post-natal lifestyle-based
intervention or a trial which may impact primary clinical
outcomes; (viii) pregnancy at post-natal baseline testing or
at any point during the 12-months of study involvement;
and (ix) surgical or medical intervention to treat obesity.
Additionally, the screening procedures have been up-
dated to reflect current practice. As a result of slow re-
cruitment initially, mail-outs were sent to women with
recent GDM history in selected geographic areas. Fol-
lowing the mail-out, a large proportion of participants
were recruited and their first eligibility screening was con-
ducted over the phone at various post-partum time points.
Therefore, the first eligibility screening took place either
during or after pregnancy depending on recruitment
strategy. This represents a change to the original protocol
which stated “Once women diagnosed with GDM express
interest in the study, the recruiter (MAGDA-DPP project
manager or research assistant) will conduct the first eligi-
bility screening generally prior to women delivering their
babies”.
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